Cargando…
Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
BACKGROUND: RET rearrangements have been reported in 30% of papillary thyroid carcinomas and 1–2% of non-small cell lung cancer (NSCLC). In these tumors, RET gene fusion product provides a constitutively active tyrosine kinase (TKR), leading to uncontrolled cellular proliferation, differentiation, a...
Autores principales: | Zhang, Quxia, Xu, Chunwei, Wang, Wenxian, Wu, Meijuan, Zhu, Youcai, Zhuang, Wu, Du, Kaiqi, Huang, Yunjian, Chen, Yanping, Wu, Biao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249982/ https://www.ncbi.nlm.nih.gov/pubmed/30429449 http://dx.doi.org/10.12659/MSM.911634 |
Ejemplares similares
-
Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023) -
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
por: Gainor, Justin F., et al.
Publicado: (2020) -
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023) -
On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012) -
RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)